Application of naringenin in preparation of anti-EHV-8 medicine

By inhibiting genome and gD protein expression in the EHV-8 virus replication stage, the technical gap in EHV-8 infection prevention and treatment was solved, and antiviral drugs suitable for equine animals were developed, which significantly inhibited EHV-8 replication and reduced lung damage, and had multiple pharmacological activities and natural low toxicity.

CN120501738APending Publication Date: 2025-08-19LIAOCHENG UNIV
2 Cites 0 Cited by

Patent Information

Application Number
CN202510838694.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-06-23
Publication Date
2025-08-19

AI Technical Summary

Technical Problem

The prior art has failed to effectively solve the infection prevention and treatment of equine herpes virus type 8 (EHV-8) in equine animals, and there is a lack of targeted antiviral drugs. The evaluation of drug targeting, effective concentration and safety in equine animal cell models is not clear.

Method used

Naringenin is used to play a role in the EHV-8 virus replication stage. By inhibiting the EHV-8 genome replication and gD protein expression, naringenin monomer, naringenin-containing plant extracts and Chinese medicine compound are developed to prepare anti-EHV-8 drugs with a maximum safe concentration of 100μM. It is suitable for the prevention and treatment of respiratory diseases, miscarriages and viral encephalitis, and reduce lung damage.

Benefits of technology

Significantly inhibit EHV-8 replication, reduce lung damage caused by EHV-8 infection, provide a variety of dosage forms to meet the needs of different patients, reduce drug research and development costs, improve drug accessibility and safety, and have multiple pharmacological activities such as anti-inflammatory and antiviral.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to the technical field of preparation of veterinary antiviral traditional Chinese medicines, in particular to application of naringenin in preparation of an anti-EHV-8 medicine, including application of a naringenin monomer, a plant extract containing the naringenin monomer and a traditional Chinese medicine compound in preparation of an EHV-8 replication inhibiting medicine. The naringenin disclosed by the invention plays an antiviral role in an EHV-8 replication stage, cannot directly inactivate viruses, has the maximum safe concentration of 100 mu M, has a remarkable inhibition effect on a plurality of strains, can reduce lung injury of a mouse model caused by EHV-8 infection, is natural in source and low in toxicity, has various pharmacological activities such as anti-inflammation and the like, and provides a reference for anti-EHV-8 clinical medication.
Need to check novelty before this filing date? Find Prior Art